Ginkgo Bioworks Holdings, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DNA research report →
Range $5 – $5
Price Chart
About the company
Ginkgo Bioworks Holdings, Inc. , together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments.
- CEO
- Jason Kelly
- IPO
- 2021
- Employees
- 485
- HQ
- Boston, MA, US
Get TickerSpark's AI analysis on DNA
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $483.59M
- P/E
- -2.03
- PEG
- -0.05
- P/S
- 5.51
- P/B
- 1.40
- EV/EBITDA
- -4.01
- Div Yield
- 0.00%
- Gross Margin
- 88.81%
- Op Margin
- -242.52%
- Net Margin
- -249.20%
- ROE
- -56.90%
- ROIC
- -27.71%
Latest fiscal year · YoY change
- Revenue
- $170.16M-25.1%
- Gross Profit
- $138.63M-26.5%
- Op Income
- $-315,278,000
- Net Income
- $-312,763,000+42.8%
- EPS
- $-5.64+46.5%
- OCF Growth
- +46.5%
- FCF Growth
- +53.2%
- 52W High
- $18.22
- 52W Low
- $5.37
- 50D MA
- $10.41
- 200D MA
- $8.63
- Beta
- 1.75
- RSI (14)
- 40
- Avg Volume
- 2.51M
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Ginkgo said Q3 showed its autonomous-lab strategy gaining real external traction, while tighter spending helped improve losses and cash burn.· November 5, 2026
- Q3 revenue was $28 million, down 6% year over year; 9M revenue was $67 million, down 37% year over year.
- R&D fell to $27 million from $51 million and G&A fell to $9 million from $14 million, helping improve profitability.
- Net loss from continuing operations improved to $41 million from $73 million, and adjusted EBITDA improved to negative $22 million from negative $53 million.
- Management highlighted first autonomous lab sale to Novo Nordisk, plus wins with MIT, Caltech, Maryland, Northwestern, ARPA-H and NSF.
- Full-year 2026 cash burn guidance was reaffirmed at $125 million to $150 million.
Revenue was $28 million in Q3 2026, down 6% versus Q3 2025; for the first 9 months of 2026, revenue was $67 million, down 37% year over year, or down about 32% excluding $7.5 million of noncash BiomEdit-related revenue in the prior-year period. R&D expense fell 48% to $27 million from $51 million, and G&A fell 32% to $9 million from $14 million. Net loss from continuing operations improved to $41 million from $73 million, and adjusted EBITDA improved to negative $22 million from negative $53 million; cash burn was $27 million in Q3 versus $28 million a year ago, and $120 million for 9M 2026 versus $124 million last year. The company ended the quarter with $285 million in cash, cash equivalents and marketable securities, no bank debt, and $86 million of restricted cash. Management reaffirmed full-year 2026 cash burn guidance of $125 million to $150 million and said it was not providing 2027 revenue guidance yet.
Jason Kelly framed the quarter as proof that Ginkgo’s shift to autonomous labs is working, saying the company reached its 2026 goal of advancing the technology and bringing it to market. He emphasized momentum from government, academic and pharma customers, calling autonomous labs a “moment” and pointing to the first big pharma hardware sale to Novo Nordisk, NSF-related academic deployments, and ARPA-H/PNNL work. His tone was upbeat and confident, especially around the idea that autonomous labs and frontier AI will increasingly reinforce each other.
Steven Coen focused on the financial cleanup and cash discipline. He noted Q3 R&D of $27 million, G&A of $9 million, net loss from continuing operations of $41 million, adjusted EBITDA of negative $22 million, and cash burn of $27 million, while also pointing out $14 million of carrying cost tied to excess leased space. He said the company ended with $285 million in cash and equivalents plus $86 million of restricted cash, and reaffirmed 2026 cash burn guidance of $125 million to $150 million. He also said revenue guidance is not being provided and that 2027 expectations will be reset in February.
Analysts asked how the cloud lab business will be monetized and whether it could become an AI data-generation service; management said the best fit is complex assays such as antibody developability and functional genomics, where Ginkgo believes it can generate harder-to-source data. Another major question was when revenue from RAC and Catalyst system sales will show up; management said revenue is recognized when systems are installed, that deployments often take 6 to 12 months, and that recurring services/software revenue follows over the life of the installed fleet. Analysts also pressed on the durability of AI frontier lab demand and Ginkgo’s cost edge versus WuXi; management said demand is real, and argued automation reduces technician and space costs enough to keep pricing competitive while customers also seek to split synthesis and testing to protect IP.
The positive case from the call is that Ginkgo appears to be turning autonomous labs from an internal platform into a sellable product with real marquee customers. Management pointed to Novo Nordisk, multiple universities, ARPA-H, NSF, and more than 20 new cloud-lab logos as signs of adoption, while also saying autonomous labs are getting attention from frontier AI companies. The financial side also looked better, with sharply lower operating expenses, improved losses and stable cash burn.
The main risks are that revenue is still declining year over year and the company is not yet giving revenue guidance, which limits visibility into how quickly the new business model will scale. Management repeatedly said system sales take time to convert into revenue, often 6 to 12 months, and that current demand still needs to work through installation cycles. There is also execution risk in proving that autonomous labs can be deployed efficiently at customer sites and that the pricing advantage versus established competitors like WuXi holds up as competitors respond.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 75.0%
- Shares Outstanding
- 64.83M
- Float Shares
- 48.59M
of shares held by institutions
191 13F filers
Buy/sell ratio 0.63. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.52M | ▲ 236.23K |
| Viking Global Investors LP | 3.58M | 0 |
| Vanguard Group Inc | 2.90M | ▲ 420.45K |
| Erste Asset Management Gmbh | 2.54M | 0 |
| Baillie Gifford & Co | 2.39M | 0 |
| Vanguard Capital Management LLC | 2.11M | ▲ 22.67K |
| Anchorage Capital Group, L.L.C. | 1.75M | 0 |
| Legal & General Group PLC | 1.67M | ▲ 7.83K |
| State Street Corp | 1.57M | ▲ 96.36K |
| Vanguard Portfolio Management LLC | 1.46M | ▲ 519.77K |
| Geode Capital Management, LLC | 1.28M | ▲ 56.32K |
| Acadian Asset Management LLC | 877.39K | ▲ 588.12K |
Held by 210 ETFs
Biggest fund positions in DNA by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Oct 16, 26 | Coen Steven P. | other | 312 |
| Oct 16, 26 | Coen Steven P. | other | 1,174 |
| Oct 19, 26 | Coen Steven P. | sell | 766 |
| Oct 16, 26 | Coen Steven P. | other | 1,174 |
| Oct 16, 26 | Coen Steven P. | other | 312 |
| Oct 16, 26 | Canton Barry | other | 10,619 |
| Oct 16, 26 | Canton Barry | other | 29,279 |
| Oct 19, 26 | Canton Barry | sell | 22,369 |
| Oct 16, 26 | Canton Barry | other | 9,762 |
| Oct 16, 26 | Canton Barry | other | 26,802 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our DNA coverage
Recent articles, reports, and earnings notes.
No research on DNA yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DNA report →Is Anthropic's IPO a Good Reason to Buy Ginkgo Bioworks Right Now?
fool.com · Nov 18
Rakovina Therapeutics Secures Exclusive Worldwide Licence to Artemis.AI™ Platform for DNA-Damage Response Oncology Drug Discovery
globenewswire.com · Nov 10
Ginkgo Bioworks: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 7
Ginkgo Bioworks Q3 Earnings Call Highlights
marketbeat.com · Nov 7
Ginkgo Bioworks Holdings, Inc. (DNA) Q3 2026 Earnings Call Transcript
seekingalpha.com · Nov 5
Ginkgo Bioworks Reports Third Quarter 2026 Results; Signs First Autonomous Lab Sale to a Top-Tier Pharma Company Novo
businesswire.com · Nov 5
Ginkgo Bioworks Holdings, Inc. (DNA) Suffers a Larger Drop Than the General Market: Key Insights
zacks.com · Oct 29
Cathie Wood Is Buying Archer Aviation Stock. Here's What History Says About Following Ark Into a Stock Down 62%.
fool.com · Oct 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.